Vindesine | |
Vindesine | |
Identifikation | |
---|---|
IUPAC navn | methyl- (5 S , 7 S , 9 S ) -9 - [(2β, 3β, 4β, 5α, 12β, 19α) -3- (aminocarbonyl) -3,4-dihydroxy-16-methoxy-1-methyl-6 , 7-didehydroaspidospermidin-15-yl] -5-ethyl-5-hydroxy-1,4,5,6,7,8,9,10-octahydro- 2H -3,7-methanoazacycloundecino [5,4- b ] indol-9-carboxylat |
N o CAS | |
N o ECHA | 100.053.330 |
ATC-kode | L01 |
DrugBank | DB00309 |
PubChem | 40839 |
ChEBI | 36373 |
SMILE |
O = C (OC) [C @] 4 (c2c (c1ccccc1n2) CCN3C [C @] (O) (CC) C [C @ H] (C3) C4) c5c (OC) cc6c (c5) [C @ @] 89 [C @ @ H] (N6C) [C @ @] (O) (C (= O) N) [C @ H] (O) [C @ @] 7 (/ C = C \ CN ( [C @@ H] 78) CC9) CC , |
InChI |
InChI: InChI = 1 / C43H55N5O7 / c1-6-39 (52) 21-25-22-42 (38 (51) 55-5,33-27 (13-17-47 (23-25) 24- 39) 26-11-8-9-12-30 (26) 45-33) 29-19-28-31 (20-32 (29) 54-4) 46 (3) 35-41 (28) 15- 18-48-16-10-14-40 (7-2.34 (41) 48) 36 (49) 43 (35.53) 37 (44) 50 / t 8-12,14,19-20,25, 34-36,45 , 49,52-53H, 6-7,13,15-18,21-24H2,1-5H3, (H2,44,50) / t25-, 34 +, 35-, 36-, 39 +, 40-, 41 -, 42 +, 43 + / m1 / s1 InChIKey: HHJUWIANJFBDHT-KOTLKJBCBW Std. InChI: InChI = 1S / C43H55N5O7 / c1-6-39 (52) 21-25-22-42 (38 (51) 55-5,33-27 (13-17-47 (23-25) 24- 39) 26-11-8-9-12-30 (26) 45-33) 29-19-28-31 (20-32 (29) 54-4) 46 (3) 35-41 (28) 15- 18-48-16-10-14-40 (7-2.34 (41) 48) 36 (49) 43 (35.53) 37 (44) 50 / h8-12,14,19-20.25, 34-36,45, 49,52-53H, 6-7,13,15-18,21-24H2,1-5H3, (H2,44,50) / t25-, 34 +, 35-, 36-, 39 +, 40-, 41- , 42 +, 43 + / m1 / s1 Std. InChIKey: HHJUWIANJFBDHT-KOTLKJBCSA-N |
Kemiske egenskaber | |
Brute formel |
C 43 H 55 N 5 O 7 |
Molar masse | 753,9261 ± 0,0414 g / mol C 68,5%, H 7,35%, N 9,29%, O 14,86%, |
Farmakokinetiske data | |
Proteinbinding | 65-75% |
Metabolisme | Lever ( Cytokrom P450 3A4 ) |
Halveringstid for eliminering. | 24 timer |
Udskillelse | |
Terapeutiske overvejelser | |
Terapeutisk klasse | Antineoplastisk |
Administrationsvej | IV |
Graviditet | Kontraindiceret |
Enheder af SI og STP, medmindre andet er angivet. | |
Den vindesin er et vincaalkaloid markedsført i Frankrig under navnet Eldisine af Eurogenerics laboratorier.
Vindesin anvendes til behandling af: